GLOW blend dosage and evidence

What is GLOW blend?

How does GLOW blend work?

Assumed to add up, with no evidence that it does. GHK-Cu delivers copper. In dishes of skin cells and in rat wound chambers, it drove the making of collagen and other skin building materials. BPC-157 and TB-500 work through the repair pathways on their own pages. One standing caveat: TB-500 is a seven building block fragment, not the thymosin beta 4 protein whose research is usually quoted for it. No study describes the three together, whether they mix safely in one acidic copper solution, or a combined dose.

What have studies in people found about GLOW blend?

None for the mix. The human record for each part is worth reading in one place. For this mix it comes to creams, gels and mixed scalp treatments for GHK-Cu, five small BPC-157 studies by routes nobody uses, and a trial of a molecule that is not in the vial.

• The mix: no study in people or animals, and no registered trial of it.
• GHK-Cu: the biggest reports come from hair clinics in Japan and India, where scalp injections that included copper peptide, given alongside other hair treatments, were followed by less hair loss. On its own, a GHK-Cu gel helped diabetic foot ulcers close, while a small study after laser treatment saw no visible difference. A new study of GHK-Cu gel on small wounds in about 60 healthy adults (NCT07437586) is under way. No published study has injected GHK-Cu by itself into people.
• BPC-157: the FDA's July 2026 review counted five human studies with fewer than 110 people in total. Two were short conference summaries. None used shots under the skin, and none gave it for more than two weeks.
• TB-500: no human study by any route. The parent protein, thymosin beta 4, has human trials. In a 9 patient eye drop study in severe dry eye, it cut eye discomfort 35.1% and damage on the eye's surface 59.1% compared with plain drops at day 56. Different molecule, different route, nine people.
• Copper: no study has measured blood copper, ceruloplasmin or copper in the urine of anyone injecting GHK-Cu, at any dose or for any length of time.

What this does not tell you: Nothing here tells you what happens when three peptides go into one syringe at a ratio of five to one to one. The GHK-Cu skin evidence is mostly creams and gels, and in the small laser study the measures taken by outside observers showed no difference. The TB-500 evidence is about a protein that is not in the vial. And the copper question, the biggest single thing in the product by weight, has no human measurement behind it at all.

What do people who took GLOW blend report?

This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.

• Skin looking brighter or more even after several weeks, usually from people also using a copper serum on the skin.
• Hair feeling thicker, reported less often and less consistently than the skin effects.
• Nagging tendon or joint pain easing, described the same way people describe BPC-157 alone.
• Stinging, redness and lumps where the needle went in, blamed on how acidic the copper solution is.
• A period of skin looking worse before it looks better, which forum users call the copper uglies. No study has checked whether this is real.
• Skin and gum darkening. That matches an FDA side effect report on an injected BPC-157 and TB-500 product, where it cleared on stopping and came back on restarting.
• No effect at all, which is a common report.

Sources: Peptide and skincare forums including r/peptides, clinic write-ups and vendor testimonial pages. No trial of this blend exists, so none of this comes from trial exit interviews or an side-effect table for the product. Most people posting are using a topical copper product at the same time as the injection, which makes attribution impossible even within the report. The FDA side-effect material comes from the agency's 2026 BPC-157 evaluation cited on this page.

The state of the research

The evidence, in charts

The studies we cite

• Study in people2006
  Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin

  After laser treatment around the mouth, 13 people used aftercare creams with or without GHK-Cu. Redness faded and wrinkles improved the same either way. The people using GHK-Cu rated their skin better.

  Thirteen patients randomised after circumoral CO2 laser resurfacing to a post-treatment regimen with or without GHK-Cu skin care products. Blinded evaluators and computer analysis found no significant difference in resolution of redness, and objective evaluation found no significant improvement in wrinkles or overall skin quality. Only patient satisfaction on a questionnaire favoured GHK-Cu, at P = 0.04. The one randomised human aesthetic trial of this ingredient is largely negative on the measures an outside observer made.

  PMID 16847171 Archives of Facial Plastic Surgery
• Study in people2026
  Topical GHK-Cu Gel for Acute Skin Wound Healing

  The only registered trial of GHK-Cu is underway and has not reported yet. Around 60 healthy adults will each get two small punched wounds, one treated with GHK-Cu gel and one with an identical plain gel under the same dressing. Each person acts as their own comparison, which is about as clean as skin research gets. It also tells you the route being tested. A gel on skin.

  A recruiting phase 2 trial, estimated 60 healthy adults, with two punch-biopsy wounds per participant randomised to GHK-Cu gel or a matching vehicle gel under identical dressings. Started February 2026, not yet reported. It is the only registered interventional GHK-Cu trial, and the route is a gel on skin.

  NCT07437586 ClinicalTrials.gov
• Study in people2015
  Thymosin beta 4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial

  The parent protein helped severe dry eye, in nine people, as an eye drop. Some got drops with it and some got the same drops without it. After eight weeks the treated eyes were more comfortable, and the damage on the surface of the eye had more than halved. Nine people is very few. And this was an eye drop of the full protein, not the fragment sold in a vial for injection.

  A 9 patient multicentre randomised double-masked placebo-controlled phase 2 trial of thymosin beta 4 eye drops in severe dry eye. At day 56 the treated group showed a 35.1% reduction in ocular discomfort and a 59.1% reduction in total corneal fluorescein staining against vehicle. This is the parent protein, as an eye drop, in nine people. It is included because it is the human evidence usually implied for the TB-500 in this vial, and it is not about that molecule or that route.

  PMID 25826322 Cornea
• Review of studies2015
  GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration

  A review of GHK. It is in your blood and falls with age. As a copper complex, it boosts collagen and speeds wound healing in animals, and cosmetic studies report firmer skin. It covers creams and cosmetics. None of it tests an injected mix.

  GHK is present in plasma and declines with age; as a copper complex it stimulates collagen and glycosaminoglycan synthesis, modulates metalloproteinases and accelerates wound healing in animal models, with cosmetic studies reporting firmer skin. The evidence surveyed is topical and cosmetic, and none of it tests an injected blend.

  PMID 26236730 BioMed Research International
• Review of studies2024
  Is Copper Still Safe for Us? What Do We Know and What Are the Latest Literature Statements?

  A 2024 review of copper safety. Your whole body holds 50 to 120 mg of copper, and the safe upper intake is 10 to 12 mg a day. It warns that even small changes in copper can be toxic. It covers copper from food and the environment, not injected peptides.

  Total body copper is 50 to 120 mg, the upper limit of normal serum copper in healthy adults is about 1.5 mg/L, the safe upper limit of average intake is 10 to 12 mg a day against a reference limit of 0.9 mg a day, and the biological half-life from diet runs 13 to 33 days. The review notes that even small changes in copper concentration can carry significant toxicity. Read a vial holding about 7.9 mg of elemental copper against those numbers, allowing that the review covers dietary and environmental copper rather than injected peptide complexes.

  PMID 39194715 Current Issues in Molecular Biology
• Review of studies2010
  An exposure-response curve for copper excess and deficiency

  A review of copper research. For copper you swallow, it puts the best intake at 2.6 mg a day, the US daily guide at 0.9 mg and the upper limit at 10 mg. No such analysis exists for injected copper peptides.

  Categorical regression across the copper literature estimates an optimal oral intake of 2.6 mg a day, against a US recommended dietary intake of 0.9 mg a day and a tolerable upper intake level of 10 mg a day. Oral intakes only, where the gut regulates absorption. No equivalent analysis exists for injected copper peptides.

  PMID 21170809 Journal of Toxicology and Environmental Health, Part B
• Review of studies2018
  Wilson disease

  A review of Wilson disease, an inherited problem where copper builds up in the liver, brain and other organs. Anyone with it, or with raised blood copper for any reason, should not inject a vial that is 71.4% copper peptide by weight.

  Mutations in ATP7B, the copper-transporting ATPase, cause pathological copper accumulation in liver, brain and other organs, managed with chelation or zinc salts. Anyone with this condition, or with a raised serum copper from any cause, should not be injecting a vial that is 71.4% copper peptide by mass.

  PMID 30190489 Nature Reviews Disease Primers
• Review of studies2026
  FDA briefing document on BPC-157 for the July 2026 PCAC meeting

  The FDA's 2026 review of BPC-157. It counted five human studies with fewer than 110 people. None used shots under the skin, and none gave it for more than two weeks. Staff found no adequate human data and mislabelled products for sale.

  FDA's evaluation counted five published human studies of BPC-157 totalling fewer than 110 subjects, none administering the peptide by subcutaneous injection and none dosing longer than two weeks. Staff found no adequate human data and mislabelled products in the market.

  Source FDA
• Animal study2000
  Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+)

  In rats. Repeated GHK-Cu shots into wound chambers grew more wound tissue and collagen. This is the closest thing to an injected GHK-Cu result anywhere, and it is a rat, not a person.

  Repeated GHK-Cu injection into rat wound chambers increased wound tissue, type I collagen and glycosaminoglycan production. This is the closest thing to an injected GHK-Cu result anywhere in the literature, and it is a rat wound chamber rather than a person.

  PMID 11121126 Journal of Investigative Dermatology
• Lab (cells in a dish)2012
  Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential

  In a lab. A drug testing lab found TB-500 is a seven building block piece of thymosin beta 4, which has 43. So one of the three parts in this mix is not the molecule its marketing names.

  A doping control laboratory identified the contents of the TB-500 formulation as Ac-LKKTETQ, the N-terminal acetylated 17 to 23 fragment of human thymosin beta 4: seven amino acids out of 43. One third of this blend by component count is not the molecule its marketing names.

  PMID 22962027 Drug Testing and Analysis